Literature DB >> 21398376

Profile of altered brain iron acquisition in restless legs syndrome.

James R Connor1, Padmavathi Ponnuru, Xin-Sheng Wang, Stephanie M Patton, Richard P Allen, Christopher J Earley.   

Abstract

Restless legs syndrome is a neurological disorder characterized by an urgency to move the legs during periods of rest. Data from a variety of sources provide a compelling argument that the amount of iron in the brain is lower in individuals with restless legs syndrome compared with neurologically normal individuals. Moreover, a significant percentage of patients with restless legs syndrome are responsive to intravenous iron therapy. The mechanism underlying the decreased iron concentrations in restless legs syndrome brains is unknown. We hypothesize that the source of the brain iron deficit is at the blood-brain interface. Thus we analysed the expression of iron management proteins in the epithelial cells of the choroid plexus and the brain microvasculature in post-mortem tissues. The choroid plexus, obtained at autopsy, from 18 neurologically normal controls and 14 individuals who had primary restless legs syndrome was subjected to histochemical staining for iron and immunostaining for iron management proteins. Iron and heavy chain ferritin staining was reduced in the epithelial cells of choroid plexus in restless legs syndrome. Divalent metal transporter, ferroportin, transferrin and its receptor were upregulated in the choroid plexus in restless legs syndrome. Microvessels were isolated from the motor cortex of 11 restless legs syndrome and 14 control brains obtained at autopsy and quantitative immunoblot analyses was performed. Expression of heavy chain ferritin, transferrin and its receptor in the microvessels from restless legs syndrome was significantly decreased compared with the controls but divalent metal protein 1, ferroportin, prohepcidin, mitochondrial ferritin and light-chain ferritin remained unchanged. The presence of an iron regulatory protein was demonstrated in the brain microvasculature and the activity of this protein is decreased in restless legs syndrome; a finding similar to our earlier report in neuromelanin cells from the substantia nigra of restless legs syndrome brains. This study reveals that there are alterations in the iron management protein profile in restless legs syndrome compared with controls at the site of blood-brain interface suggesting fundamental differences in brain iron acquisition in individuals with restless legs syndrome. Furthermore, the decrease in transferrin receptor expression in the microvasculature in the presence of relative brain iron deficiency reported in restless legs syndrome brains may underlie the problems associated with brain iron acquisition in restless legs syndrome. The consistent finding of loss of iron regulatory protein activity in restless legs syndrome brain tissue further implicates this protein as a factor in the underlying cause of the iron deficiency in the restless legs syndrome brain. The data herein provide evidence for regulation of iron uptake and storage within brain microvessels that challenge the existing paradigm that the blood-brain barrier is merely a transport system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21398376      PMCID: PMC3069701          DOI: 10.1093/brain/awr012

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  50 in total

1.  Is ferroportin-hepcidin signaling altered in restless legs syndrome?

Authors:  Stacey L Clardy; Xinsheng Wang; Philip J Boyer; Christopher J Earley; Richard P Allen; James R Connor
Journal:  J Neurol Sci       Date:  2006-06-08       Impact factor: 3.181

Review 2.  Insight into the pathophysiology of restless legs syndrome.

Authors:  C J Earley; R P Allen; J L Beard; J R Connor
Journal:  J Neurosci Res       Date:  2000-12-01       Impact factor: 4.164

3.  Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset.

Authors: 
Journal:  Sleep Med       Date:  2000-02-01       Impact factor: 3.492

Review 4.  Iron and iron management proteins in neurobiology.

Authors:  J R Connor; S L Menzies; J R Burdo; P J Boyer
Journal:  Pediatr Neurol       Date:  2001-08       Impact factor: 3.372

5.  Transferrin is required for normal distribution of 59Fe and 54Mn in mouse brain.

Authors:  E A Malecki; B M Cook; A G Devenyi; J L Beard; J R Connor
Journal:  J Neurol Sci       Date:  1999-11-30       Impact factor: 3.181

6.  Ferritin subunits in CSF are decreased in restless legs syndrome.

Authors:  Stacey L Clardy; Christopher J Earley; Richard P Allen; John L Beard; James R Connor
Journal:  J Lab Clin Med       Date:  2006-02

7.  Iron status and restless legs syndrome in the elderly.

Authors:  S T O'Keeffe; K Gavin; J N Lavan
Journal:  Age Ageing       Date:  1994-05       Impact factor: 10.668

8.  Restless legs syndrome and pregnancy.

Authors:  M Manconi; V Govoni; A De Vito; N T Economou; E Cesnik; I Casetta; G Mollica; L Ferini-Strambi; E Granieri
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

9.  Iron and the restless legs syndrome.

Authors:  E R Sun; C A Chen; G Ho; C J Earley; R P Allen
Journal:  Sleep       Date:  1998-06-15       Impact factor: 5.849

10.  Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain.

Authors:  Rashid Deane; Wei Zheng; Berislav V Zlokovic
Journal:  J Neurochem       Date:  2004-02       Impact factor: 5.372

View more
  66 in total

1.  Investigation of unmedicated early onset restless legs syndrome by voxel-based morphometry, T2 relaxometry, and functional MR imaging during the night-time hours.

Authors:  P N Margariti; L G Astrakas; S G Tsouli; G M Hadjigeorgiou; S Konitsiotis; M I Argyropoulou
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-15       Impact factor: 3.825

Review 2.  Pathogenic implications of iron accumulation in multiple sclerosis.

Authors:  Rachel Williams; Cassandra L Buchheit; Nancy E J Berman; Steven M LeVine
Journal:  J Neurochem       Date:  2011-11-11       Impact factor: 5.372

3.  A role for sex and a common HFE gene variant in brain iron uptake.

Authors:  Kari A Duck; Elizabeth B Neely; Ian A Simpson; James R Connor
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-28       Impact factor: 6.200

4.  Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome.

Authors:  Sahil Chawla; Seema Gulyani; Richard P Allen; Christopher J Earley; Xu Li; Peter Van Zijl; Dimitrios Kapogiannis
Journal:  Sleep       Date:  2019-07-08       Impact factor: 5.849

5.  A novel model for brain iron uptake: introducing the concept of regulation.

Authors:  Ian A Simpson; Padmavathi Ponnuru; Marianne E Klinger; Roland L Myers; Kavi Devraj; Christopher L Coe; Gabriele R Lubach; Anthony Carruthers; James R Connor
Journal:  J Cereb Blood Flow Metab       Date:  2014-10-15       Impact factor: 6.200

6.  Medications for sleep disturbances in children.

Authors:  Barbara T Felt; Ronald D Chervin
Journal:  Neurol Clin Pract       Date:  2014-02

Review 7.  Restless Legs Syndrome and Other Movement Disorders of Sleep-Treatment Update.

Authors:  Aaro V Salminen; Juliane Winkelmann
Journal:  Curr Treat Options Neurol       Date:  2018-11-09       Impact factor: 3.598

8.  Dysregulated iron metabolism in the choroid plexus in fragile X-associated tremor/ataxia syndrome.

Authors:  Jeanelle Ariza; Craig Steward; Flora Rueckert; Matt Widdison; Robert Coffman; Atiyeh Afjei; Stephen C Noctor; Randi Hagerman; Paul Hagerman; Verónica Martínez-Cerdeño
Journal:  Brain Res       Date:  2014-12-09       Impact factor: 3.252

Review 9.  Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology.

Authors:  Richard P Allen
Journal:  Sleep Med Clin       Date:  2015-07-15

Review 10.  Restless legs syndrome-current therapies and management of augmentation.

Authors:  Claudia Trenkwalder; Juliane Winkelmann; Yuichi Inoue; Walter Paulus
Journal:  Nat Rev Neurol       Date:  2015-07-28       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.